- Conditions
- HIV-1 Infection
- Interventions
- FTC/RPV/TDF, EFV/FTC/TDF
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 799 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 83
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 59 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–8
of 8
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Human Immunodeficiency Virus (HIV)
- Interventions
- Rilpivirine, Placebo
- Drug
- Lead sponsor
- PATH
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 136 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2017
- U.S. locations
- 2
- States / cities
- Newark, New Jersey • The Bronx, New York
- Conditions
- HIV-1 Infection
- Interventions
- Emtricitabine/rilpivirine/tenofovir disoproxil fumarate
- Drug
- Lead sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 14 more
- Conditions
- HIV-DDI
- Interventions
- Riociguat (Adempas, BAY 63-2521), ATRIPLA, COMPLERA, STRIBILD, TRIUMEQ, Antiretroviral protease inhibitor
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 2
- States / cities
- Orlando, Florida • Boston, Massachusetts
- Conditions
- HIV-1 Infection
- Interventions
- FTC/RPV/TAF, FTC/RPV/TDF Placebo, FTC/RPV/TDF, FTC/RPV/TAF Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 632 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 75
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 56 more
- Conditions
- HIV-1 Infection
- Interventions
- FTC/RPV/TDF, PI, RTV, NRTIs
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 482 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 66
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 45 more
- Conditions
- HIV-1 Infection
- Interventions
- Not listed
- Lead sponsor
- Prema Menezes, PhD, PA-C
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- HIV-1 Infection
- Interventions
- FTC/RPV/TDF
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 18
- States / cities
- Long Beach, California • Los Angeles, California • San Diego, California + 12 more